Clinical Trial

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-02-13; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-03-13
Trial Details
NCT Number NCT06832410
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Type 1 Diabetes, Kidney Transplant
Enrollment 10 participants
Start Date 2025-03-31
Primary Completion 2026-09-17 (estimated)
Study Completion 2027-09-17 (estimated)
Updated on ClinicalTrials.gov 2026-03-23